Search Results

cases consist of renal cell carcinomas (RCCs), which are genetically and histologically distinct from cancers of the renal pelvis. An increased understanding of RCC biology coupled with new clinical trials data have resulted in the availability of

metastatic clear cell RCC Describe second-line management of patients with metastatic clear cell RCC I n the past 5 years, 6 new agents were approved for the treatment of renal cell carcinoma (RCC). These can be broadly categorized into 2 groups: vascular

In the past 10 years, much has changed in the management of advanced renal cell carcinoma (RCC; Figure 1 ). The treatment of early-stage disease has become less morbid, with the widespread adoption of robotic surgical techniques and the increased

Chromophobe renal cell carcinoma (chRCC) is the third most frequent kidney cancer histologic subtype, accounting for approximately 5% of all RCC cases. At diagnosis, chRCC is generally confined to the kidney but can metastasize. At advanced stages

Treatment of advanced renal cell carcinoma (RCC) has changed drastically in the past decade. The mTORC1 inhibitors, everolimus and temsirolimus (also known as rapalogs ), have been shown to be key drugs for use in first-line treatment 1 and

Petrylak D Thompson S . Cytotoxic chemotherapy for advanced renal cell carcinoma . Urol Clin North Am 1993 ; 20 : 303 – 321 . 3 Atkins MB Regan M McDermott D . Update on the role of interleukin 2 and other cytokines in the treatment of

The incidence of renal cell carcinoma (RCC) has been steadily increasing for decades. 1 The mainstay of treatment for clinically localized disease is radical nephrectomy and, when technically feasible, partial nephrectomy. Yet, up to 20% to 30

Identify those patients with metastatic RCC who may benefit the most from SRS treatment Renal Cell Carcinoma and the Case for Local Therapy for Metastatic Disease Renal cell carcinoma (RCC) is the seventh most common malignancy in the United

. Combination Phase III Trials Using Immune Checkpoint Blockade in First-Line Metastatic Renal Cell Carcinoma referred after surgery by urologists to medical oncologists, removing the potential impact of systemic therapy on surgical timing and outcome

: casting doubt on the efficacy of early intervention . Urology 2001 ; 57 : 1013 – 1015 . 3 Hollenbeck BK Taub DA Miller DC . National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology